<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Ovarian germ cell tumors: Pathology, epidemiology, clinical manifestations, and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Ovarian germ cell tumors: Pathology, epidemiology, clinical manifestations, and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Ovarian germ cell tumors: Pathology, epidemiology, clinical manifestations, and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David M Gershenson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barbara Goff, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alberto S Pappo, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rochelle L Garcia, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alana Chakrabarti, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 30, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ovarian germ cell tumors (OGCTs) are derived from primordial germ cells of the ovary  (
         <a class="graphic graphic_figure graphicRef72286" href="/z/d/graphic/72286.html" rel="external">
          figure 1
         </a>
         ). They may be benign (eg, mature teratoma) or malignant (eg, immature teratoma, dysgerminoma, yolk sac tumor, mixed germ cell neoplasm).
        </p>
        <p>
         The pathology, epidemiology, clinical manifestations, and diagnosis of OGCTs, as well as the treatment of benign OGCTs are reviewed here. Treatment of malignant OGCTs as well as clinical features, diagnosis, and treatment of epithelial ovarian carcinoma are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3197.html" rel="external">
          "Treatment of malignant germ cell tumors of the ovary"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83397.html" rel="external">
          "Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1585803904">
         <span class="h1">
          TYPES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The histologic types of OGCTs that arise from the ovary are similar to those developing in the testes of males  (
         <a class="graphic graphic_table graphicRef76682" href="/z/d/graphic/76682.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">
          "Anatomy and pathology of testicular tumors"
         </a>
         .)
        </p>
        <p>
         OGCTs can be broadly divided into those that differentiate toward embryo-like neoplasms (eg, teratomas and their subtypes, dysgerminomas) and those that differentiate primarily toward extraembryonic fetal-derived (placenta-like) cell populations or a mixture of both. Categories include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Teratomas
         </strong>
         – The designation teratoma refers to a neoplasm that differentiates toward somatic-type cell populations (typically including cell populations that would normally derive from ectoderm, endoderm, and mesoderm) that can be typical of either adult or embryonic development and are foreign to the anatomic site in which they are found. They are divided into four categories:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mature (cystic or solid, benign)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immature (malignant)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Malignant due to a component of another somatic malignant neoplasm
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Monodermal or highly specialized
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dysgerminomas
         </strong>
         – These are the female version of the male seminoma and are essentially comprised of immature germ cells. (See
         <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">
          "Anatomy and pathology of testicular tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Yolk sac tumors
         </strong>
         – These are carcinomas (epithelial neoplasms) that differentiate toward yolk sac/primitive placenta forms (also called endodermal sinus tumors).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mixed germ cell tumors
         </strong>
         – These are tumors with two or more types of malignant OGCTs. The most common combination is a dysgerminoma and yolk sac tumor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rare OGCTs
         </strong>
         – Rare OGCTs include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pure embryonal carcinomas
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nongestational choriocarcinomas
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pure polyembryoma
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2858606014">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         OGCTs comprise approximately 20 to 25 percent of ovarian neoplasms overall, but only account for about 5 percent of all malignant ovarian neoplasms [
         <a href="#rid1">
          1,3,4
         </a>
         ].
        </p>
        <p>
         OGCTs are found primarily in young females between 10 and 30 years of age, representing 70 percent of ovarian neoplasms in this age group [
         <a href="#rid5">
          5
         </a>
         ]. Worldwide, the incidence is the highest in Eastern Asia for females &lt;30 years, and the highest in Central America for those &gt;30 years [
         <a href="#rid6">
          6
         </a>
         ]. For unclear reasons, in the Surveillance, Epidemiology, and End Results (SEER) United States national cancer database, malignant OGCTs occurred more frequently among Hispanic Americans and Asian/Pacific Islanders compared with non-Hispanic White and non-Hispanic Black Americans [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Among
         <strong>
          malignant
         </strong>
         OGCTs, dysgerminoma, immature teratoma, yolk sac tumors, and mixed germ cell tumors account for 90 percent of cases [
         <a href="#rid1">
          1,4
         </a>
         ]. The distribution of histologic types among
         <strong>
          malignant
         </strong>
         ovarian germ cell tumors is found in the table  (
         <a class="graphic graphic_table graphicRef72483" href="/z/d/graphic/72483.html" rel="external">
          table 2
         </a>
         ) and discussed in detail below. (See
         <a class="local">
          'Histopathology and clinical behavior'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
        </p>
        <p class="headingAnchor" id="H1348144678">
         <span class="h2">
          Nonspecific signs and symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients may be asymptomatic or present with one or more of the following signs and symptoms [
         <a href="#rid8">
          8-12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abdominal enlargement
         </strong>
         – OGCTs tend to grow rapidly, and abdominal enlargement may occur from the mass itself, ascites, or both. OGCTs tend to be large (median size, 16 cm), and ascites is reported in 20 percent of cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abdominal pain
         </strong>
         – From rupture or torsion. Rupture (pre- or intraoperative) and torsion are reported in 20 and 5 percent of cases, respectively. The pain may be acute and can be misdiagnosed as appendicitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Precocious puberty
         </strong>
         – Presumably from human chorionic gonadotropin (hCG) production.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptoms of pregnancy
         </strong>
         – From hCG production.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         – Other symptoms, such as fever or vaginal bleeding, occur in approximately 10 percent of patients.
        </p>
        <p>
        </p>
        <p>
         Abdominal pain and an abdominal mass are present in most (85 percent) patients with an OGCT [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2953039865">
         <span class="h2">
          Signs and symptoms characteristic of a specific OGCT
         </span>
         <span class="headingEndMark">
          —
         </span>
         While most ovarian germ cell tumors (OGCTs) present with nonspecific signs or symptoms, some presentations are more specific for certain OGCTs. For example, rupture of a mature teratoma with spillage of sebaceous material into the abdominal cavity can present with shock. By contrast, monodermal highly specialized teratomas usually present with hyperthyroidism or carcinoid symptoms  (
         <a class="graphic graphic_table graphicRef63079" href="/z/d/graphic/63079.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Mature teratoma (dermoid)'
         </a>
         below and
         <a class="local">
          'Monodermal highly specialized teratomas'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3406326632">
         <span class="h2">
          Rare presentations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anti-N-methyl-D-aspartate receptor encephalitis is a rare condition associated with either mature or immature teratomas [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Anti-NMDA receptor encephalitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1211847246">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnostic evaluation is similar to that of patients with other adnexal masses and includes a complete medical history and physical examination. (See
         <a class="medical medical_review" href="/z/d/html/83704.html" rel="external">
          "Approach to the patient with an adnexal mass", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H801973750">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with other adnexal masses, pelvic ultrasound is typically the first-line imaging study used to characterize an adnexal mass, though patients with an acute presentation may be initially imaged with computed tomography. (See
         <a class="local">
          'Nonspecific signs and symptoms'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3208.html" rel="external">
          "Adnexal mass: Ultrasound categorization"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3814186281">
         <span class="h2">
          Laboratory testing
         </span>
        </p>
        <p class="headingAnchor" id="H3964675459">
         <span class="h3">
          Tumor markers
         </span>
         <span class="headingEndMark">
          —
         </span>
         OGCTs often produce hormones, which can be measured in the serum, providing a highly sensitive and variably specific marker for the presence of certain histologic components  (
         <a class="graphic graphic_table graphicRef55817" href="/z/d/graphic/55817.html" rel="external">
          table 4
         </a>
         ). Some tumor markers are present in some, but not all, tumors of a specific histology. As an example, tumor markers produced by tumor types may include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          human chorionic gonadotropic (hCG)
         </strong>
         – Embryonal cell carcinomas and ovarian choriocarcinomas, mixed germ cell tumors, and some dysgerminomas.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alpha-fetoprotein (AFP)
         </strong>
         – Yolk sac tumors, embryonal cell carcinomas and polyembryoma carcinomas, mixed germ cell tumors, and some immature teratomas [
         <a href="#rid15">
          15,16
         </a>
         ]; most dysgerminomas are associated with a normal AFP.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lactate dehydrogenase
         </strong>
         <strong>
          (LDH)
         </strong>
         – Dysgerminomas.
        </p>
        <p>
        </p>
        <p>
         If elevated, tumor markers are useful for monitoring the response to treatment and for posttreatment surveillance.
        </p>
        <p class="headingAnchor" id="H862944383">
         <span class="h3">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         A pregnancy test should be performed for all reproductive-age patients to exclude an ectopic pregnancy or other pregnancy-related adnexal mass. (See
         <a class="medical medical_review" href="/z/d/html/3204.html" rel="external">
          "Adnexal mass: Differential diagnosis", section on 'Pregnancy-related'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of OGCTs is made by histology at time of surgical excision. The diagnosis is strongly suggested preoperatively by the presence of an adnexal mass on pelvic imaging and an elevated level of an associated tumor marker. (See
         <a class="local">
          'Imaging'
         </a>
         above and
         <a class="local">
          'Tumor markers'
         </a>
         above.)
        </p>
        <p>
         For benign cystic mature teratomas, the diagnosis can be made with reasonable confidence using pelvic ultrasonography; however, removal of the cyst is still advised. (See
         <a class="local">
          'Mature teratoma (dermoid)'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3208.html" rel="external">
          "Adnexal mass: Ultrasound categorization", section on 'Mature teratoma'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2057423318">
         <span class="h1">
          HISTOPATHOLOGY AND CLINICAL BEHAVIOR
         </span>
        </p>
        <p class="headingAnchor" id="H4170656920">
         <span class="h2">
          Teratomas
         </span>
        </p>
        <p class="headingAnchor" id="H4126783036">
         <span class="h3">
          Mature teratoma (dermoid)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most teratomas are cystic (mature cystic teratoma; dermoid cyst) and are composed of mature differentiated elements including tissue of ectodermal (eg, skin, hair follicles, sebaceous glands), mesodermal (eg, muscle, urinary), and endodermal (eg, lung, gastrointestinal) origin [
         <a href="#rid17">
          17
         </a>
         ]. The mechanism by which these cysts develop is possibly by failure of meiosis II or from a premeiotic cell in which meiosis I has failed [
         <a href="#rid18">
          18
         </a>
         ]. In rare instances, a teratoma is solid but is composed entirely of benign-appearing heterogeneous collections of tissue and organized structures derived from all three cell layers.
        </p>
        <p>
         Mature cystic teratomas account for more than 95 percent of all ovarian teratomas are the most common ovarian tumor in females in the second and third decade of life [
         <a href="#rid19">
          19
         </a>
         ]. Mature teratomas at nonovarian sites (eg, vaginal wall) have also been described [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         The characteristic macroscopic appearance of a benign cystic teratoma is a multicystic mass that contains hair, teeth, and/or skin that is mixed into sebaceous, thick, sticky, and often foul-smelling material  (
         <a class="graphic graphic_picture graphicRef70608" href="/z/d/graphic/70608.html" rel="external">
          picture 1
         </a>
         ). A solid prominence (Rokitansky protuberance) is located at the junction between the teratoma and normal ovarian tissue [
         <a href="#rid1">
          1
         </a>
         ]. The greatest cellular variety is found in the area of this junction, which should therefore be examined carefully by the pathologist to exclude immature/malignant components.
        </p>
        <p>
         Most patients with mature teratomas are asymptomatic. If present, symptoms depend on the size of the mass. Torsion is not uncommon. Rupture of dermoid cysts with spillage of sebaceous material into the abdominal cavity can occur, but is uncommon. Shock and hemorrhage are the immediate sequelae of rupture; a marked granulomatous reaction (chemical peritonitis) may subsequently develop and lead to formation of dense adhesions.
        </p>
        <p>
         Most mature solid teratomas are unilateral. Bilateral mature teratomas occur in 10 to 17 percent of cases  (
         <a class="graphic graphic_table graphicRef109390" href="/z/d/graphic/109390.html" rel="external">
          table 5
         </a>
         ) and can be synchronous and metachronous [
         <a href="#rid21">
          21
         </a>
         ]; peritoneal implants have also been described [
         <a href="#rid22">
          22
         </a>
         ]. Grossly, it may be difficult/impossible to differentiate these neoplasms from malignant solid immature teratomas, which are almost always solid, and they therefore may require sampling from multiple sites. (See
         <a class="local">
          'Immature teratoma'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2767256623">
         <span class="h4">
          Malignant transformation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mature teratomas are almost always benign [
         <a href="#rid19">
          19
         </a>
         ]. Development of malignant (somatic) neoplasm occurs in 0.2 to 2 percent of mature cystic teratomas [
         <a href="#rid23">
          23-25
         </a>
         ], and comprises 2.9 percent of all malignant OGCTs  (
         <a class="graphic graphic_table graphicRef72483" href="/z/d/graphic/72483.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid26">
          26
         </a>
         ]. Although any of the components of a mature cystic teratoma may develop malignant neoplasm, squamous cell carcinoma arising from the ectoderm is the most common secondary neoplasm [
         <a href="#rid22">
          22,27
         </a>
         ]. Other possible malignant neoplasms include (but are not limited to) basal cell carcinoma, melanoma, adenocarcinoma, sarcoma, and thyroid carcinoma. When malignant transformation has occurred within a teratoma, treatment must be tailored to the transformed histology.
        </p>
        <p>
         Risk factors for malignant neoplasm in a mature cystic teratoma include age over 45 years (mean age, 50 years versus 33 years for benign teratomas), tumor diameter &gt;10 cm, rapid growth, and characteristic findings on imaging (eg, low-resistance intratumor flow on Doppler) [
         <a href="#rid22">
          22,27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3208.html" rel="external">
          "Adnexal mass: Ultrasound categorization", section on 'Mature teratoma'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2832093739">
         <span class="h3">
          Immature teratoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immature teratomas (also called malignant teratoma, teratoblastoma, or embryonal teratoma) comprise less than 1 percent of ovarian teratomas and are most common in the first two decades of life [
         <a href="#rid17">
          17
         </a>
         ]. They comprise 35.6 percent of all malignant OGCTs  (
         <a class="graphic graphic_table graphicRef72483" href="/z/d/graphic/72483.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Immature teratomas are typically composed of tissue from the three germ cell layers: ectoderm, mesoderm, and endoderm, arranged in a haphazard manner. Histologically, there are varying amounts of immature tissue, most frequently with neural differentiation, although immature stromal elements can also be present.
        </p>
        <p>
         Immature teratomas are the only OGCTs that are histologically graded. The grade of differentiation (ranging from I [well differentiated] to III [poorly differentiated]) is based on the proportion of tissue in histologic sections containing immature neural elements [
         <a href="#rid8">
          8
         </a>
         ]. Grade is an important indicator of the risk for extraovarian spread. The presence of foci of yolk sac tumor in immature teratomas generally reflects more aggressive behavior and a worse outcome [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="local">
          'Yolk sac tumor'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H59065061">
         <span class="h3">
          Monodermal highly specialized teratomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         The specialized or monodermal teratomas are a rare and remarkable subset of teratomas that consist of a predominant mature histologic cell type. The most common of these are struma ovarii and carcinoid (a well-differentiated neuroendocrine neoplasm). They are usually unilateral, although a contralateral teratoma may be present.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Struma ovarii
         </strong>
         – Struma ovarii is a teratoma predominantly composed of mature thyroid tissue [
         <a href="#rid17">
          17
         </a>
         ]. The secretion of thyroid hormones results in clinical hyperthyroidism in 25 to 35 percent of such patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Struma ovarii is uncommon, comprising approximately 2.7 percent of ovarian teratomas. It is often associated with a mature cystic teratoma and rarely with a cystadenoma. Most cases of struma ovarii are benign and can be managed by excision of the ovary or by unilateral salpingo-oophorectomy. However, malignant change may occur, but it is exceedingly rare [
         <a href="#rid29">
          29,30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7829.html" rel="external">
          "Struma ovarii"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carcinoid neoplasms
         </strong>
         – Ovarian carcinoid neoplasms are rare [
         <a href="#rid31">
          31
         </a>
         ]. Primary ovarian carcinoid neoplasms are usually unilateral, localized to the ovary, and indistinguishable histologically from metastasis. They have similar appearances to those that arise in any other site (eg, gastrointestinal, respiratory). They are comprised of nests and cords of relatively bland cells (uniform cells without nuclear atypia) with endocrine features and a fine vascular network.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some carcinoid neoplasms secrete bioactive polypeptides and amines, producing a constellation of symptoms, predominantly flushing and diarrhea  (
         <a class="graphic graphic_table graphicRef63079" href="/z/d/graphic/63079.html" rel="external">
          table 3
         </a>
         ). Carcinoid syndrome develops in approximately one-third of cases, and it can develop without hepatic metastases due to direct venous drainage from the ovary into the systemic circulation (see
         <a class="medical medical_review" href="/z/d/html/2613.html" rel="external">
          "Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts", section on 'Ovary'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2614.html" rel="external">
          "Clinical features of carcinoid syndrome", section on 'Clinical features'
         </a>
         ). 5-hydroxyindoleacetic acid, a metabolite of serotonin  (
         <a class="graphic graphic_figure graphicRef51368" href="/z/d/graphic/51368.html" rel="external">
          figure 2
         </a>
         ), is excreted in the urine and can be used to confirm the diagnosis of carcinoid syndrome and as a marker of disease activity in patients with advanced disease or the carcinoid syndrome. (See
         <a class="medical medical_review" href="/z/d/html/2622.html" rel="external">
          "Diagnosis of carcinoid syndrome and tumor localization", section on 'Biochemical testing for carcinoid syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Carcinoid tumors metastatic to the ovary are even more rare; they tend to be bilateral and arise from primary ileal carcinoid tumors [
         <a href="#rid32">
          32
         </a>
         ]. In such cases, disseminated abdominal disease is common.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mixed struma ovarii and carcinoid
         </strong>
         – The presence of a mixed struma ovarii and carcinoid is even more rare. These lesions usually follow a benign course.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1842730741">
         <span class="h2">
          Dysgerminoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although dysgerminomas are relatively uncommon among all ovarian neoplasms (accounting for only an approximate 2 percent), they account for 33 percent of malignant OGCTs  (
         <a class="graphic graphic_table graphicRef72483" href="/z/d/graphic/72483.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid26">
          26
         </a>
         ]. The majority of cases (75 percent) arise in adolescents and young females, in whom they account for approximately one-third of all ovarian malignant neoplasms [
         <a href="#rid33">
          33
         </a>
         ]. As such, they are one of the more common ovarian malignant neoplasms detected during pregnancy. Nevertheless, dysgerminoma can occur at any age; case reports have described patients with dysgerminoma between 7 months and 70 years of age.
        </p>
        <p>
         Although dysgerminomas are malignant, the degree of histologic atypia is variable, and only an approximate one-third behave aggressively. The neoplasm is composed of undifferentiated germ cells, large vesicular cells with clear cytoplasm, well-defined cell boundaries, and centrally placed regular nuclei; the overall appearance is sometimes described as resembling "fried eggs"  (
         <a class="graphic graphic_picture graphicRef79890" href="/z/d/graphic/79890.html" rel="external">
          picture 2
         </a>
         ). The stroma is infiltrated by clusters of small lymphocytes and frequently contains granulomas. Dysgerminoma is the ovarian counterpart of testicular seminoma, and histologically it has a similar appearance (see
         <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">
          "Anatomy and pathology of testicular tumors"
         </a>
         ). Grossly, dysgerminoma appears as a lobulated mass that is firm and cream colored or pale tan  (
         <a class="graphic graphic_picture graphicRef138484" href="/z/d/graphic/138484.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The growth of dysgerminomas is usually rapid; as a result, patients often present with abdominal enlargement and pain due to rupture with hemoperitoneum or torsion. Menstrual abnormalities may occur if the tumor is hormonally active. Dysgerminomas can contain syncytiotrophoblastic giant cells that produce placental alkaline phosphatase, and lactate dehydrogenase (LDH) [
         <a href="#rid34">
          34,35
         </a>
         ]. Serial measurements of these markers can be useful for monitoring disease  (
         <a class="graphic graphic_table graphicRef55817" href="/z/d/graphic/55817.html" rel="external">
          table 4
         </a>
         ). In addition, human chorionic gonadotropin (hCG) is produced in 3 to 5 percent of dysgerminomas [
         <a href="#rid36">
          36
         </a>
         ]. In general, dysgerminomas do not produce alpha-fetoprotein (AFP), although borderline elevations (&lt;16 ng/mL) are described in case series, but most often in the setting of mixed germ cell tumors that contain a yolk sac element [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Bilateral ovarian disease is more common with dysgerminoma than with any other malignant OGCT. While 75 percent of patients with dysgerminomas present with stage I disease  (
         <a class="graphic graphic_table graphicRef113545" href="/z/d/graphic/113545.html" rel="external">
          table 6
         </a>
         ), the contralateral ovary is involved in 10 to 15 percent of cases  (
         <a class="graphic graphic_table graphicRef109390" href="/z/d/graphic/109390.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3472536715">
         <span class="h3">
          Association with gonadoblastoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dysgerminomas may develop within a gonadoblastoma (a benign or in situ germ cell ovarian neoplasm composed of germ cells and sex cord stroma) in phenotypic females who have a Y chromosome. Included in this group are patients with pure gonadal dysgenesis (46XY), mixed gonadal dysgenesis (45X/46XY), or complete androgen insensitivity (formerly called testicular feminization; 46XY). Occasional patients may have features of Turner syndrome. These latter patients may have a 45X, 45X/46XX, or 45X/46XY karyotype. (See
         <a class="medical medical_review" href="/z/d/html/7391.html" rel="external">
          "Clinical manifestations and diagnosis of Turner syndrome", section on 'Risk of malignancy'
         </a>
         .)
        </p>
        <p>
         These tumors may produce either testosterone or estrogens. Clinical presentation may include developmental abnormalities of the genitalia, primary amenorrhea, or virilization. Although gonadoblastoma may be overgrown by dysgerminoma, as occurs in approximately 50 percent of cases, other malignant germ cell components may predominate, including yolk sac tumor, immature teratoma, embryonal carcinoma, or choriocarcinoma. Thus, karyotyping is recommended for all patients with the operative finding of gonadoblastoma, with or without a coexistent malignant germ cell tumor, or young patients who present with an ovarian mass or masses and either primary amenorrhea or abnormalities of the genitalia.
        </p>
        <p>
         It is important to determine whether a gonadoblastoma is present, since oophorectomy should be performed in these patients to prevent the development of gonadal neoplasia, although the age at which the procedure is performed depends upon the underlying etiology [
         <a href="#rid39">
          39,40
         </a>
         ]. Patients at risk for having dysgenetic gonads ideally should be identified preoperatively; frozen section is not reliable.
        </p>
        <p class="headingAnchor" id="H3331473545">
         <span class="h2">
          Yolk sac tumor
         </span>
         <span class="headingEndMark">
          —
         </span>
         Yolk sac tumors (also known as endodermal sinus tumors) make up 14 to 20 percent of all malignant OGCTs  (
         <a class="graphic graphic_table graphicRef72483" href="/z/d/graphic/72483.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid26">
          26,41
         </a>
         ]. These neoplasms usually occur in young females; the median age at presentation is 23 years and one-third of patients are premenarchal [
         <a href="#rid42">
          42,43
         </a>
         ].
        </p>
        <p>
         Histologically, these epithelial neoplasms consist of tubules or spaces lined by single layers of flattened cuboidal cells, reticular stroma, and scattered globules  (
         <a class="graphic graphic_picture graphicRef83636" href="/z/d/graphic/83636.html" rel="external">
          picture 4
         </a>
         ) [
         <a href="#rid9">
          9
         </a>
         ]. Invaginated papillary structures with a central vessel (Schiller-Duval bodies) are found within some of the spaces  (
         <a class="graphic graphic_picture graphicRef58480" href="/z/d/graphic/58480.html" rel="external">
          picture 5
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Tumor growth can be very rapid and aggressive with extensive intraperitoneal dissemination.
        </p>
        <p class="headingAnchor" id="H1017573589">
         <span class="h2">
          Mixed germ cell tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mixed germ cell neoplasms account for 5.3 percent of all malignant OGCTs  (
         <a class="graphic graphic_table graphicRef72483" href="/z/d/graphic/72483.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid26">
          26
         </a>
         ]. They consist of two or more admixed types of OGCTs; components of dysgerminoma mixed with a yolk sac tumor are found most commonly.
        </p>
        <p>
         In cases in which a dysgerminoma component is present, the contralateral ovary is involved 10 percent of the time. The neoplasms may secrete tumor markers, such as lactate dehydrogenase, alpha-fetoprotein, or human chorionic gonadotropin, depending upon the type of tissue present.
        </p>
        <p class="headingAnchor" id="H4059024047">
         <span class="h2">
          Embryonal carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Embryonal carcinoma accounts for 4 percent of malignant OGCTs  (
         <a class="graphic graphic_table graphicRef72483" href="/z/d/graphic/72483.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid26">
          26,44
         </a>
         ]. It resembles the more common embryonal carcinoma of the testis and is one of the most aggressive ovarian malignant neoplasms. The average age at diagnosis is 15 years. (See
         <a class="medical medical_review" href="/z/d/html/2949.html" rel="external">
          "Anatomy and pathology of testicular tumors"
         </a>
         .)
        </p>
        <p>
         Histologically, embryonal carcinomas are epithelial and therefore form nests and sometimes papillary or gland-like structures. Many atypical mitotic figures are usually present, reflecting the high proliferative activity of the neoplastic cells. Multinucleated giant cells resembling syncytial cells may be present; these are the cells that produce hCG [
         <a href="#rid17">
          17
         </a>
         ]. Some embryonal carcinomas also make AFP  (
         <a class="graphic graphic_table graphicRef55817" href="/z/d/graphic/55817.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
         Clinically, they usually present with an abdominal or pelvic mass and abdominal pain [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2792851630">
         <span class="h2">
          Choriocarcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nongestational choriocarcinoma is a rare and highly malignant type of OGCT [
         <a href="#rid45">
          45
         </a>
         ]. Choriocarcinomas are more commonly of placental than ovarian origin; the estimated incidence of a primary ovarian choriocarcinoma is 1 in 369,000,000. They comprise 2.1 percent of all malignant OGCTs  (
         <a class="graphic graphic_table graphicRef72483" href="/z/d/graphic/72483.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid26">
          26
         </a>
         ]. A choriocarcinoma of ovarian origin derives from an extraembryonic differentiation of malignant germ cells. This highly malignant germ cell epithelial neoplasm differentiates towards trophoblastic structures and often contains other malignant germ cell elements.
        </p>
        <p>
         Nongestational ovarian choriocarcinoma is histologically identical to primary gestational choriocarcinoma associated with pregnancy [
         <a href="#rid46">
          46-48
         </a>
         ]. The two entities can be distinguished by DNA analysis; the presence of paternal DNA within the tumor indicates a gestational (placental) origin [
         <a href="#rid49">
          49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3230.html" rel="external">
          "Gestational trophoblastic disease: Pathology", section on 'Choriocarcinoma'
         </a>
         .)
        </p>
        <p>
         All choriocarcinomas produce hCG, which may cause isosexual precocity in young girls and irregular vaginal bleeding of uterine origin. Serum levels of hCG are useful for monitoring response to treatment.
        </p>
        <p>
         Like gestational choriocarcinomas, those arising in the ovary tend to develop early hematogenous metastasis to several different sites, including lung, liver, brain, bone, vagina, and other viscera. In contrast to gestational choriocarcinomas, those arising in the ovary are relatively chemoresistant.
        </p>
        <p class="headingAnchor" id="H501325990">
         <span class="h2">
          Polyembryoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polyembryoma is a malignant germ call neoplasm that is very rare and, in most instances, is associated with other germ cell elements such as immature teratoma. It is composed of embryoid bodies that morphologically resemble normal embryos [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         It usually occurs in young females and may present with signs of pseudopuberty as serum hCG and AFP concentrations can be elevated.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          STAGING AND SURGICAL TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         In virtually all cases of OGCTs, surgery is required for definitive histologic diagnosis, treatment, and staging (if malignant). Oophorectomy, ovarian cystectomy, or resection of the ovarian mass can be performed, depending on the clinical situation, and tissue sent for frozen section. Confirmation of the diagnosis should be obtained prior to definitive surgical treatment.
        </p>
        <p>
         Most patients with OGCTs present with stage IA disease (limited to one ovary); bilateral disease occurs in 10 to 12 percent of cases [
         <a href="#rid50">
          50
         </a>
         ]. Tumors with a propensity for bilateral ovarian involvement include benign cystic teratoma, dysgerminoma, or a tumor with components of dysgerminoma (mixed germ cell tumor).
        </p>
        <p class="headingAnchor" id="H2773347653">
         <span class="h2">
          Mature cystic teratomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with a mature cystic teratoma, ovarian cystectomy is suggested to make a definitive diagnosis, preserve ovarian tissue, and avoid potential problems such as torsion, rupture, or development of malignant components. For patients who have completed childbearing, salpingo-oophorectomy is also acceptable treatment. Benign cystic teratomas do not recur if surgically resected.
        </p>
        <p>
         Mature cystic teratomas may be removed via either laparoscopy or laparotomy. While intact removal is preferred, rupture can occur, and the abdomen should be copiously irrigated to avoid a chemical peritonitis from any spillage of the sebaceous cyst fluid. (See
         <a class="medical medical_review" href="/z/d/html/3304.html" rel="external">
          "Oophorectomy and ovarian cystectomy", section on 'Laparoscopic/minimally invasive surgery cystectomy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1286163362">
         <span class="h2">
          All other OGCTs (malignant)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Malignant germ cell tumors are staged according to the International Federation of Gynecology and Obstetrics (FIGO) staging system for epithelial ovarian cancer  (
         <a class="graphic graphic_table graphicRef113545" href="/z/d/graphic/113545.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid51">
          51
         </a>
         ]. In brief, stage I disease is confined to the ovaries, stage II includes extension into other pelvic tissues, stage III refers to disease that has spread beyond the pelvis or to retroperitoneal lymph nodes but remains in the abdomen, and stage IV refers to the presence of distant metastasis or involvement of liver parenchyma.
        </p>
        <p>
         Management of malignant OGCTs is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3197.html" rel="external">
          "Treatment of malignant germ cell tumors of the ovary"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H126681595">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119533.html" rel="external">
          "Society guideline links: Ovarian, fallopian tube, and peritoneal cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Types
         </strong>
         – Ovarian germ cell tumors (OGCTs) are derived from primordial germ cells of the ovary  (
         <a class="graphic graphic_figure graphicRef72286" href="/z/d/graphic/72286.html" rel="external">
          figure 1
         </a>
         ). They may be benign or malignant. The histologic types of OGCTs can be found in the table  (
         <a class="graphic graphic_table graphicRef76682" href="/z/d/graphic/76682.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Types'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – OGCTs comprise approximately 20 to 25 percent of ovarian neoplasms overall, but account for only an approximate 5 percent of all malignant ovarian neoplasms. They arise primarily in young patients between 10 and 30 years of age and represent 70 percent of ovarian neoplasms in this age group. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The distribution of histologic types among
         <strong>
          malignant
         </strong>
         ovarian germ cell tumors is found in the table  (
         <a class="graphic graphic_table graphicRef72483" href="/z/d/graphic/72483.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Patients may be asymptomatic or present with nonspecific symptoms such as abdominal enlargement, abdominal pain, precocious puberty, symptoms of pregnancy, fever, and/or vaginal bleeding. Abdominal pain and an abdominal mass are present in most patients. (See
         <a class="local">
          'Nonspecific signs and symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other presentations may be specific for certain OGCTs (eg, rupture of a mature teratoma can present with shock, monodermal highly specialized teratomas usually present with hyperthyroidism or carcinoid symptoms  (
         <a class="graphic graphic_table graphicRef63079" href="/z/d/graphic/63079.html" rel="external">
          table 3
         </a>
         )). (See
         <a class="local">
          'Signs and symptoms characteristic of a specific OGCT'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         –The diagnostic evaluation is similar to that of patients with other adnexal masses, and includes a complete medical history, physical examination, and pregnancy test in reproductive-age patients. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above and
         <a class="local">
          'Other'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         As with other adnexal masses, pelvic ultrasound is typically the first-line imaging study used. (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         OGCTs often produce tumor markers (eg, human chorionic gonadotropin [hCG], alpha-fetoprotein [AFP], lactate dehydrogenase [LDH]  (
         <a class="graphic graphic_table graphicRef55817" href="/z/d/graphic/55817.html" rel="external">
          table 4
         </a>
         )), providing a highly sensitive and variably specific marker for the presence of certain histologic components. (See
         <a class="local">
          'Tumor markers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of OGCTs is made by histology at time of surgical excision. The diagnosis is strongly suggested preoperatively by the presence of an adnexal mass on pelvic imaging and an elevated level of an associated tumor marker  (
         <a class="graphic graphic_table graphicRef55817" href="/z/d/graphic/55817.html" rel="external">
          table 4
         </a>
         ), if present. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The diagnosis of a benign cystic mature teratoma is also strongly suggested by characteristic findings on pelvic ultrasonography. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mature teratoma
         </strong>
         – The most common OGCT is the
         <strong>
          benign
         </strong>
         mature cystic teratoma (dermoid cyst), which can be bilateral. Approximately 1 percent contain a secondary malignancy arising from one of the components, usually a squamous cell cancer. Ovarian cystectomy or oophorectomy provides definitive diagnosis and treatment. (See
         <a class="local">
          'Mature teratoma (dermoid)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dysgerminoma
         </strong>
         – Dysgerminoma is the most common
         <strong>
          malignant
         </strong>
         ovarian germ cell tumor. Bilateral ovarian disease is more common than with any other ovarian germ cell tumor. These tumors are less likely to produce tumor markers than other malignant germ cell tumors  (
         <a class="graphic graphic_table graphicRef55817" href="/z/d/graphic/55817.html" rel="external">
          table 4
         </a>
         ), but LDH is often elevated. (See
         <a class="local">
          'Dysgerminoma'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Talerman A. Germ cell tumours of the ovary. In: Blaustein's Pathology of the Female Genital Tract, Kurman RJ (Ed), Springer Verlag, New York 1994. p.849.
         </li>
         <li class="breakAll">
          Serov SF, Scully RE, Sobin LJ. Histological typing of ovarian tumors. In: International Histological Classification of Tumors, World Health Organization, Geneva 1973.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sagae S, Kudo R. Surgery for germ cell tumors. Semin Surg Oncol 2000; 19:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tewari K, Cappuccini F, Disaia PJ, et al. Malignant germ cell tumors of the ovary. Obstet Gynecol 2000; 95:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zalel Y, Piura B, Elchalal U, et al. Diagnosis and management of malignant germ cell ovarian tumors in young females. Int J Gynaecol Obstet 1996; 55:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hubbard AK, Poynter JN. Global incidence comparisons and trends in ovarian germ cell tumors by geographic region in girls, adolescents and young women: 1988-2012. Gynecol Oncol 2019; 154:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norris HJ, Zirkin HJ, Benson WL. Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases. Cancer 1976; 37:2359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurman RJ, Norris HJ. Endodermal sinus tumor of the ovary: a clinical and pathologic analysis of 71 cases. Cancer 1976; 38:2404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershenson DM, Del Junco G, Herson J, Rutledge FN. Endodermal sinus tumor of the ovary: the M. D. Anderson experience. Obstet Gynecol 1983; 61:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershenson DM, del Junco G, Silva EG, et al. Immature teratoma of the ovary. Obstet Gynecol 1986; 68:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershenson DM, Del Junco G, Copeland LJ, Rutledge FN. Mixed germ cell tumors of the ovary. Obstet Gynecol 1984; 64:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ueda G, Abe Y, Yoshida M, Fujiwara T. Embryonal carcinoma of the ovary: a six-year survival. Int J Gynaecol Obstet 1990; 31:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ihara T, Ohama K, Satoh H, et al. Histologic grade and karyotype of immature teratoma of the ovary. Cancer 1984; 54:2988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mann JR, Raafat F, Robinson K, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 2000; 18:3809.
          </a>
         </li>
         <li class="breakAll">
          DiSaia PJ, Creasman WT. Germ cell, stromal and other ovarian tumors. In: Clinical Gynecologic Oncology, 7th, Mosby-Elsevier, 2007. p.381.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caspi B, Lerner-Geva L, Dahan M, et al. A possible genetic factor in the pathogenesis of ovarian dermoid cysts. Gynecol Obstet Invest 2003; 56:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ayhan A, Bukulmez O, Genc C, et al. Mature cystic teratomas of the ovary: case series from one institution over 34 years. Eur J Obstet Gynecol Reprod Biol 2000; 88:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacKinnon R, Elmezzi K, Phippen N. Vaginal dermoid cyst. Am J Obstet Gynecol 2021; 225:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gang S, Yang HB, Kim HY. A 17-year experience on bilaterality of ovarian germ cell tumors in pediatric population and its clinical implications: A single-center study. J Pediatr Surg 2022; 57:1221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hackethal A, Brueggmann D, Bohlmann MK, et al. Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data. Lancet Oncol 2008; 9:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westhoff C, Pike M, Vessey M. Benign ovarian teratomas: a population-based case-control study. Br J Cancer 1988; 58:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comerci JT Jr, Licciardi F, Bergh PA, et al. Mature cystic teratoma: a clinicopathologic evaluation of 517 cases and review of the literature. Obstet Gynecol 1994; 84:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh P, Yordan EL, Wilbanks GD, et al. Malignancy associated with benign cystic teratomas (dermoid cysts) of the ovary. Singapore Med J 1988; 29:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith HO, Berwick M, Verschraegen CF, et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol 2006; 107:1075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dos Santos L, Mok E, Iasonos A, et al. Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature. Gynecol Oncol 2007; 105:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodruff JD, Protos P, Peterson WF. Ovarian teratomas. Relationship of histologic and ontogenic factors to prognosis. Am J Obstet Gynecol 1968; 102:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robboy SJ, Shaco-Levy R, Peng RY, et al. Malignant struma ovarii: an analysis of 88 cases, including 27 with extraovarian spread. Int J Gynecol Pathol 2009; 28:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaco-Levy R, Bean SM, Bentley RC, Robboy SJ. Natural history of biologically malignant struma ovarii: analysis of 27 cases with extraovarian spread. Int J Gynecol Pathol 2010; 29:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis KP, Hartmann LK, Keeney GL, Shapiro H. Primary ovarian carcinoid tumors. Gynecol Oncol 1996; 61:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strosberg J, Nasir A, Cragun J, et al. Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases. Gynecol Oncol 2007; 106:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           La Vecchia C, Morris HB, Draper GJ. Malignant ovarian tumours in childhood in Britain, 1962-78. Br J Cancer 1983; 48:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levato F, Martinello R, Campobasso C, Porto S. LDH and LDH isoenzymes in ovarian dysgerminoma. Eur J Gynaecol Oncol 1995; 16:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PE, Morris JM. Serum lactic dehydrogenase: a tumor marker for dysgerminoma. Obstet Gynecol 1988; 72:511.
          </a>
         </li>
         <li class="breakAll">
          Germ cell tumors. In: WHO Classification of Tumours of Female Reproductive Organs, 4th ed, Kurman RJ, Carcangiu ML, Herrington CS, et al (Eds), IARC, 2014. Vol 6, p.57.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon A, Lipton D, Woodruff JD. Dysgerminoma: a review of 158 cases from the Emil Novak Ovarian Tumor Registry. Obstet Gynecol 1981; 58:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boran N, Tulunay G, Caliskan E, et al. Pregnancy outcomes and menstrual function after fertility sparing surgery for pure ovarian dysgerminomas. Arch Gynecol Obstet 2005; 271:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krasna IH, Lee ML, Smilow P, et al. Risk of malignancy in bilateral streak gonads: the role of the Y chromosome. J Pediatr Surg 1992; 27:1376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Arce MA, Costigan C, Gosden JR, et al. Further evidence consistent with Yqh as an indicator of risk of gonadal blastoma in Y-bearing mosaic Turner syndrome. Clin Genet 1992; 41:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujita M, Inoue M, Tanizawa O, et al. Retrospective review of 41 patients with endodermal sinus tumor of the ovary. Int J Gynecol Cancer 1993; 3:329.
          </a>
         </li>
         <li class="breakAll">
          Berek JS, Hacker NF. Nonepithelial ovarian and fallopian tube cancers. In: Practical Gynecologic Oncology, 4th, Berek JS, Hacker NF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.511.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah JP, Kumar S, Bryant CS, et al. A population-based analysis of 788 cases of yolk sac tumors: A comparison of males and females. Int J Cancer 2008; 123:2671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-Rustum NR, Aghajanian C. Management of malignant germ cell tumors of the ovary. Semin Oncol 1998; 25:235.
          </a>
         </li>
         <li class="breakAll">
          DiSaia PJ, Creasman WT. Germ cell, stromal and other ovarian tumors. In: Clinical Gynecologic Oncology, 7th, Mosby-Elsevier, 2007. p.379.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheeler CA, Davis S, Degefu S, et al. Ovarian choriocarcinoma: a difficult diagnosis of an unusual tumor and a review of the hook effect. Obstet Gynecol 1990; 75:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steigrad SJ, Cheung AP, Osborn RA. Choriocarcinoma co-existent with an intact pregnancy: case report and review of the literature. J Obstet Gynaecol Res 1999; 25:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cunanan RG Jr, Lippes J, Tancinco PA. Choriocarcinoma of the ovary with coexisting normal pregnancy. Obstet Gynecol 1980; 55:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher RA, Newlands ES, Jeffreys AJ, et al. Gestational and nongestational trophoblastic tumors distinguished by DNA analysis. Cancer 1992; 69:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pectasides D, Pectasides E, Kassanos D. Germ cell tumors of the ovary. Cancer Treat Rev 2008; 34:427.
          </a>
         </li>
         <li class="breakAll">
          Berek JS. Epithelial ovarian cancer. In: Practical Gynecologic Oncology, 4th, Berek JS, Hacker NF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.443.
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3236 Version 44.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Talerman A. Germ cell tumours of the ovary. In: Blaustein's Pathology of the Female Genital Tract, Kurman RJ (Ed), Springer Verlag, New York 1994. p.849.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Serov SF, Scully RE, Sobin LJ. Histological typing of ovarian tumors. In: International Histological Classification of Tumors, World Health Organization, Geneva 1973.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10883028" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Surgery for germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10636515" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Malignant germ cell tumors of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8910077" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Diagnosis and management of malignant germ cell ovarian tumors in young females.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31303255" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Global incidence comparisons and trends in ovarian germ cell tumors by geographic region in girls, adolescents and young women: 1988-2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26742998" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Cancer statistics, 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1260722" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/63318" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Endodermal sinus tumor of the ovary: a clinical and pathologic analysis of 71 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6185892" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Endodermal sinus tumor of the ovary: the M. D. Anderson experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3763073" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Immature teratoma of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6204258" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Mixed germ cell tumors of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1690671" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Embryonal carcinoma of the ovary: a six-year survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18851928" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6498772" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Histologic grade and karyotype of immature teratoma of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11078494" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11078494" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14614249" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A possible genetic factor in the pathogenesis of ovarian dermoid cysts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10690674" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Mature cystic teratomas of the ovary: case series from one institution over 34 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33713684" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Vaginal dermoid cyst.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35387741" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A 17-year experience on bilaterality of ovarian germ cell tumors in pediatric population and its clinical implications: A single-center study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19038764" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3166898" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Benign ovarian teratomas: a population-based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8008317" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Mature cystic teratoma: a clinicopathologic evaluation of 517 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2841767" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Malignancy associated with benign cystic teratomas (dermoid cysts) of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16648414" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Incidence and survival rates for female malignant germ cell tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17240432" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4176444" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Ovarian teratomas. Relationship of histologic and ontogenic factors to prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19696610" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Malignant struma ovarii: an analysis of 88 cases, including 27 with extraovarian spread.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20407319" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Natural history of biologically malignant struma ovarii: analysis of 27 cases with extraovarian spread.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8626144" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Primary ovarian carcinoid tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17475313" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6311234" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Malignant ovarian tumours in childhood in Britain, 1962-78.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7664770" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : LDH and LDH isoenzymes in ovarian dysgerminoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3405571" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Serum lactic dehydrogenase: a tumor marker for dysgerminoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3405571" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Serum lactic dehydrogenase: a tumor marker for dysgerminoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7279343" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Dysgerminoma: a review of 158 cases from the Emil Novak Ovarian Tumor Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15007601" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Pregnancy outcomes and menstrual function after fertility sparing surgery for pure ovarian dysgerminomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1479492" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Risk of malignancy in bilateral streak gonads: the role of the Y chromosome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1633643" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Further evidence consistent with Yqh as an indicator of risk of gonadal blastoma in Y-bearing mosaic Turner syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11578366" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Retrospective review of 41 patients with endodermal sinus tumor of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11578366" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Retrospective review of 41 patients with endodermal sinus tumor of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18767035" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A population-based analysis of 788 cases of yolk sac tumors: A comparison of males and females.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9562457" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Management of malignant germ cell tumors of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9562457" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Management of malignant germ cell tumors of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1689478" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Ovarian choriocarcinoma: a difficult diagnosis of an unusual tumor and a review of the hook effect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10467793" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Choriocarcinoma co-existent with an intact pregnancy: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7366928" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Choriocarcinoma of the ovary with coexisting normal pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1346098" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Gestational and nongestational trophoblastic tumors distinguished by DNA analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18378402" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Germ cell tumors of the ovary.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
